1. Home
  2. CYTK vs CNS Comparison

CYTK vs CNS Comparison

Compare CYTK & CNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • CNS
  • Stock Information
  • Founded
  • CYTK 1997
  • CNS 1986
  • Country
  • CYTK United States
  • CNS United States
  • Employees
  • CYTK N/A
  • CNS N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • CNS Investment Managers
  • Sector
  • CYTK Health Care
  • CNS Finance
  • Exchange
  • CYTK Nasdaq
  • CNS Nasdaq
  • Market Cap
  • CYTK 6.0B
  • CNS 5.1B
  • IPO Year
  • CYTK 2004
  • CNS 2004
  • Fundamental
  • Price
  • CYTK $48.18
  • CNS $102.88
  • Analyst Decision
  • CYTK Buy
  • CNS Hold
  • Analyst Count
  • CYTK 16
  • CNS 3
  • Target Price
  • CYTK $83.67
  • CNS $92.00
  • AVG Volume (30 Days)
  • CYTK 1.2M
  • CNS 198.9K
  • Earning Date
  • CYTK 11-06-2024
  • CNS 10-16-2024
  • Dividend Yield
  • CYTK N/A
  • CNS 2.35%
  • EPS Growth
  • CYTK N/A
  • CNS 0.80
  • EPS
  • CYTK N/A
  • CNS 2.68
  • Revenue
  • CYTK $3,219,000.00
  • CNS $496,822,000.00
  • Revenue This Year
  • CYTK N/A
  • CNS $7.84
  • Revenue Next Year
  • CYTK $911.39
  • CNS $16.64
  • P/E Ratio
  • CYTK N/A
  • CNS $37.29
  • Revenue Growth
  • CYTK N/A
  • CNS 0.21
  • 52 Week Low
  • CYTK $30.68
  • CNS $56.23
  • 52 Week High
  • CYTK $110.25
  • CNS $110.67
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 39.67
  • CNS 48.73
  • Support Level
  • CYTK $49.64
  • CNS $97.94
  • Resistance Level
  • CYTK $59.39
  • CNS $100.60
  • Average True Range (ATR)
  • CYTK 2.23
  • CNS 2.60
  • MACD
  • CYTK -0.54
  • CNS -0.54
  • Stochastic Oscillator
  • CYTK 4.88
  • CNS 21.68

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for close to two thirds of its $79.3 billion in managed assets at the end of January 2024. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 42% (27%) of its managed assets (base management fees) from institutional clients, 45% (52%) from open-end funds, and 13% (21%) from closed-end funds.

Share on Social Networks: